Management of advanced colorectal cancer: state of the art

被引：77

作者：

Saunders, M.

Iveson, T.

机构：

[1] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England

[2] Southampton Gen Hosp, Southampton SO16 6YD, Hants, England

来源：

BRITISH JOURNAL OF CANCER | 2006年 / 95卷 / 02期

关键词：

colorectal cancer; first-line; 5-fluorouracil; irinotecan; oxaliplatin; targeted agents;

D O I：

10.1038/sj.bjc.6603233

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer ( CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new cytotoxic agents, irinotecan and oxaliplatin, into first- line regimens. The concept of planned sequential therapy involving three active agents during the course of a patient's treatment is evolving. Coupled with the integrated use of targeted monoclonal antibodies, we can now expect overall survival rates for advanced disease to exceed 20 months. This review considers current treatments and suggests where future progress may occur.

引用

页码：131 / 138

页数：8

共 57 条

[1] Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study [J].

Alberts, SR ;

Horvath, WL ;

Stcrnfeld, WC ;

Goldberg, RM ;

Mahoney, MR ;

Dakhil, SR ;

Levitt, R ;

Rowland, K ;

Nair, S ;

Sargent, DJ ;

Donohue, JH .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9243-9249

[2] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[3]

[Anonymous], COCHRANE DATABASE SY

[4]

Carlini LE, 2005, CLIN CANCER RES, V11, P1226

[5] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[6] Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].

Cunningham, D ;

Pyrhönen, S ;

James, RD ;

Punt, CJA ;

Hickish, TF ;

Heikkila, R ;

Johannesen, TB ;

Starkhammar, H ;

Topham, CA ;

Awad, L ;

Jacques, C ;

Herait, P .

LANCET, 1998, 352 (9138) :1413-1418

[7] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[8] Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study [J].

deGramont, A ;

Basset, JF ;

Milan, C ;

Rougier, P ;

Bouche, O ;

Etienne, PL ;

Morvan, F ;

Louvet, C ;

Guillot, C ;

Francois, E ;

Bedenne, L .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :808-815

[9]

DIAZRUBIO E, 2005, J CLIN ONCOL, V26, pS254

[10] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

← 1 2 3 4 5 6 →